A nonbiodegradable scaffold-free cell sheet of genome-engineered mesenchymal stem cells inhibits development of acute kidney injury

Park, Hye-Jeong; Kong, Min Jung; Jang, Hyo‐Ju; Cho, Jeong‐In; Park, Eui‐Jung; Lee, Inkyu; Frøkiær, Jørgen; Nørregaard, Rikke; Park, Kwon Moo; Kwon, Tae‐Hwan

doi:10.1016/j.kint.2020.07.043

Cited by 12 publications

(14 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionsupporting

confidence: 92%

“…Our study is consistent with the previous studies that MSCs have played a leading role in regenerative medicine due to their self‐renewal ability and potential to differentiate into various cell types. 40 , 41 , 42 , 43 To the best of our knowledge, this is the first study to show MSCs could be isolated from postnatal rat hard palates. Previous studies have reported embryo palatal MSCs, 44 , 45 , 46 palatal periosteum MSCs, 18 and MSCs from adipose tissue of the hard palate.…”

Section: Discussionmentioning

confidence: 85%

See 1 more Smart Citation

Light‐controlled scaffold‐ and serum‐free hard palatal‐derived mesenchymal stem cell aggregates for bone regeneration

Jiang

Shao

et al. 2022

Bioengineering & Transla Med

View full text Add to dashboard Cite

Cell aggregates that mimic in vivo cell–cell interactions are promising and powerful tools for tissue engineering. This study isolated a new, easily obtained, population of mesenchymal stem cells (MSCs) from rat hard palates named hard palatal‐derived mesenchymal stem cells (PMSCs). The PMSCs were positive for CD90, CD44, and CD29 and negative for CD34, CD45, and CD146. They exhibited clonogenicity, self‐renewal, migration, and multipotent differentiation capacities. Furthermore, this study fabricated scaffold‐free 3D aggregates using light‐controlled cell sheet technology and a serum‐free method. PMSC aggregates were successfully constructed with good viability. Transplantation of the PMSC aggregates and the PMSC aggregate‐implant complexes significantly enhanced bone formation and implant osseointegration in vivo, respectively. This new cell resource is easy to obtain and provides an alternative strategy for tissue engineering and regenerative medicine.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 85%

Light‐controlled scaffold‐ and serum‐free hard palatal‐derived mesenchymal stem cell aggregates for bone regeneration

Jiang

Shao

et al. 2022

Bioengineering & Transla Med

View full text Add to dashboard Cite

show abstract

“…Several studies utilizing mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord are ongoing, and cumulated reports of the beneficial effects of cellular therapeutics for renal IR and renal disorders are indicated [ 23 , 24 , 25 ] through the actions of paracrine effect of stem-cell-released MVs and miRNAs. In the present study, we preconditioned DEX-treated ADSC-MVs to increase more biofactors with higher migrating activity in vitro and improve renal H/R injury in vitro and IR injury in vivo.…”

Section: Discussionmentioning

confidence: 99%

Intrarenal Arterial Transplantation of Dexmedetomidine Preconditioning Adipose Stem-Cell-Derived Microvesicles Confers Further Therapeutic Potential to Attenuate Renal Ischemia/Reperfusion Injury through miR-122-5p/Erythropoietin/Apoptosis Axis

et al. 2022

View full text Add to dashboard Cite

Intravenous adipose mesenchymal stem cells (ADSCs) attenuate renal ischemia/reperfusion (IR) injury but with major drawbacks, including the lack of a specific homing effect after systemic infusion, cell trapping in the lung, and early cell death in the damaged microenvironment. We examined whether intrarenal arterial transplantation of dexmedetomidine (DEX) preconditioning ADSC-derived microvesicles (DEX-MVs) could promote further therapeutic potential to reduce renal IR injury. We evaluated the effect of DEX-MVs on NRK-52E cells migration, hypoxia/reoxygenation (H/R)-induced cell death, and reactive oxygen species (ROS) amount and renal IR model in rats. IR was established by bilateral 45 min ischemia followed by 4 h reperfusion. Intrarenal MVs or DEX-MVs were administered prior to ischemia. Renal oxidative stress, hemodynamics and function, western blot, immunohistochemistry, and tubular injury scores were determined. The miR-122-5p expression in kidneys was analyzed using microarrays and quantitative RT-PCR and its action target was predicted by TargetScan. DEX-MVs were more efficient than MVs to increase migration capability and to further decrease H/R-induced cell death and ROS level in NRK-52E cells. Consistently, DEX-MVs were better than MV in increasing CD44 expression, improving IR-depressed renal hemodynamics and renal erythropoietin expression, inhibiting IR-enhanced renal ROS level, tubular injury score, miR-122-5p expression, pNF-κB expression, Bax/caspase 3/poly(ADP-ribose) polymerase (PARP)-mediated apoptosis, blood urea nitrogen, and creatinine levels. The use of NRK-52E cells confirmed that miR-122-5p mimic via inhibiting erythropoietin expression exacerbated Bax-mediated apoptosis, whereas miR-122-5p inhibitor via upregulating erythropoietin and Bcl-2 expression reduced apoptosis. In summary, intrarenal arterial DEX-MV conferred further therapeutic potential to reduce renal IR injury through the miR-122-5p/erythropoietin/apoptosis axis.

show abstract

“…Engineering cell sheet with mesenchymal stem cells is a very important branch in the field of the regenerative medicine, which has been growing for the past 20 years. In addition to the use of the cell sheet for cell therapy, numerous other applications could be used (Figure 1): Formation of complex tissue, by stacking different type of cell sheets [1]; Gene therapy [211][212][213];…”

Section: Discussionmentioning

confidence: 99%

Development of Multilayer Mesenchymal Stem Cell Cell Sheets

Ochiai¹,

Niihara²,

Oliva³

2021

IJTM

View full text Add to dashboard Cite

Cell and gene therapies have been developing dramatically over the past decade. To face and adapt to the development of these new therapies, the Food and Drug Administration (FDA) wrote and updated new guidelines from 2016 and keep updating them. Mesenchymal stem cells (MSCs) are the most used cells for treatment, far ahead from the induced pluripotent stem cells (iPSCs), based on registered clinical trials at clinicaltrials.gov. They are widely used because of their differentiation capacity and their anti-inflammatory properties, but some controversies still require clear answers. Additional studies are needed to determine the dosage, the number, and the route of injections (location and transplantation method), and if allogenic MSCs are safe compared to autologous MSC injection, including their long-term effect. In this review, we summarize the research our company is conducting with the adipose stromal cells in engineering cell sheets and their potential application.

show abstract

A nonbiodegradable scaffold-free cell sheet of genome-engineered mesenchymal stem cells inhibits development of acute kidney injury

Cited by 12 publications

References 52 publications

Light‐controlled scaffold‐ and serum‐free hard palatal‐derived mesenchymal stem cell aggregates for bone regeneration

Light‐controlled scaffold‐ and serum‐free hard palatal‐derived mesenchymal stem cell aggregates for bone regeneration

Intrarenal Arterial Transplantation of Dexmedetomidine Preconditioning Adipose Stem-Cell-Derived Microvesicles Confers Further Therapeutic Potential to Attenuate Renal Ischemia/Reperfusion Injury through miR-122-5p/Erythropoietin/Apoptosis Axis

Development of Multilayer Mesenchymal Stem Cell Cell Sheets

Contact Info

Product

Resources

About